{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:36:12Z","timestamp":1785476172926,"version":"3.56.0"},"reference-count":62,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background: Inequity in prostate cancer detection can be assessed by relating the diagnostic intensity to the incidence rate of advanced disease in different population groups, according to factors such as socioeconomic status or ethnicity.\nMethods: We used nationwide Swedish register data from Prostate Cancer data Base Sweden 5.0 and Statistics Sweden, which enabled us to estimate incidence rates of low-risk prostate cancer (a proxy for diagnostic activity) and advanced disease (locally advanced and\/or metastatic) across population groups according to household income, country of birth, and neighborhood-level characteristics.\nResults: We found a gradient in the age-standardized incidence of low-risk prostate cancer across income groups, from 60 per 100,000\/year in men with high to 34 per 100,000\/year in men with low household income: adjusted incidence rate ratio (IRR) 0.65 (95% confidence interval [CI] 0.59\u20130.71). The gradient in the incidence of advanced disease had the opposite direction, from 44 to 60 per 100,000\/year, IRR 1.43 (95% CI 1.31\u20131.56). Immigrants from a non-Nordic country (nearly 40% from Asia) had lower incidence rates of both low-risk (IRR 0.47, 95% CI 0.42\u20130.53) and advanced disease (IRR 0.65, 95% CI 0.58\u20130.73) than men born in a Nordic country. Neighborhood-level analysis considering economic standard, share of immigrants, and degree of urbanization did not clearly differentiate the incidence of advanced disease.\nInterpretation: Our results suggest that measures to facilitate early detection of prostate cancer should be targeted to men with a low income. A low diagnostic activity for prostate cancer among immigrants from countries with low background risk may not imply unjustified social disparity.<\/jats:p>","DOI":"10.2340\/1651-226x.2025.43399","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T02:04:16Z","timestamp":1747361056000},"page":"677-684","source":"Crossref","is-referenced-by-count":3,"title":["Sociodemographic disparities in incidence rates of advanced and low-risk prostate cancer as a proxy for diagnostic activity"],"prefix":"10.2340","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-1973","authenticated-orcid":false,"given":"Ulf","family":"Str\u00f6mberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1189-9950","authenticated-orcid":false,"given":"Carl","family":"Bonander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7181-7083","authenticated-orcid":false,"given":"Hans","family":"Garmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4624-3767","authenticated-orcid":false,"given":"Mats","family":"Lambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8306-0687","authenticated-orcid":false,"given":"P\u00e4r","family":"Stattin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9198-9445","authenticated-orcid":false,"given":"Ola","family":"Bratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"111855","doi-asserted-by":"crossref","unstructured":"Clegg LX, Reichman ME, Miller BA, Hankey BF, Singh GK, Lin YD, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control. 2009;20:417\u201335.","DOI":"10.1007\/s10552-008-9256-0"},{"key":"111856","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10552-008-9256-0","DOI":"10.1007\/s10552-008-9256-0"},{"key":"111857","doi-asserted-by":"crossref","unstructured":"Houston KA, King J, Li J, Jemal A. Trends in prostate cancer incidence rates and prevalence of prostate specific antigen screening by socioeconomic status and regions in the United States, 2004 to 2013. J Urol. 2018;199:676\u201382.","DOI":"10.1016\/j.juro.2017.09.103"},{"key":"111858","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.juro.2017.09.103","DOI":"10.1016\/j.juro.2017.09.103"},{"key":"111859","doi-asserted-by":"crossref","unstructured":"Barclay ME, Abel GA, Greenberg DC, Rous B, Lyratzopoulos G. Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact. Br J Cancer. 2021;124:1320\u20139.","DOI":"10.1038\/s41416-021-01279-z"},{"key":"111860","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41416-021-01279-z","DOI":"10.1038\/s41416-021-01279-z"},{"key":"111861","doi-asserted-by":"crossref","unstructured":"Khadhra HB, Saint F, Trecherel E, Lapotre-Ledoux B, Zerkly S, Ganry O. Relationship between socioeconomic status and prostate cancer (incidence, aggressiveness, treatment with curative intent, and mortality): a spatial analysis using population-based cancer registry data. Rev Epidemiol Sante Publique. 2021;69:329\u201336.","DOI":"10.1016\/j.respe.2021.07.007"},{"key":"111862","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.respe.2021.07.007","DOI":"10.1016\/j.respe.2021.07.007"},{"key":"111863","doi-asserted-by":"crossref","unstructured":"Dodkins J, Cook A, Mayne E, Parry M, Nossiter J, Payne H, et al. Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluation. BMJ Oncol. 2025;4:e000643.","DOI":"10.1136\/bmjonc-2024-000643"},{"key":"111864","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmjonc-2024-000643","DOI":"10.1136\/bmjonc-2024-000643"},{"key":"111865","doi-asserted-by":"crossref","unstructured":"Ammitzboll G, Levinsen AKG, Kjaer TK, Ebbestad FE, Horsbol TA, Saltbaek L, et al. Socioeconomic inequality in cancer in the Nordic countries. A systematic review. Acta Oncol. 2022;61:1317\u201331.","DOI":"10.1080\/0284186X.2022.2143278"},{"key":"111866","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2022.2143278","DOI":"10.1080\/0284186X.2022.2143278"},{"key":"111867","doi-asserted-by":"crossref","unstructured":"Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer \u2013 results from a prospective, population-based randomized controlled trial. Eur Urol. 2007;51:659\u201364.","DOI":"10.1016\/j.eururo.2006.07.012"},{"key":"111868","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2006.07.012","DOI":"10.1016\/j.eururo.2006.07.012"},{"key":"111869","doi-asserted-by":"crossref","unstructured":"Hugosson J, Roobol MJ, M\u00e5nsson M, Tammela TLJ, Zappa M, Nelen V, et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol. 2019;76:43\u201351.","DOI":"10.1016\/j.eururo.2019.02.009"},{"key":"111870","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2019.02.009","DOI":"10.1016\/j.eururo.2019.02.009"},{"key":"111871","doi-asserted-by":"crossref","unstructured":"Bratt O, Auvinen A, Arnsrud Godtman R, Hellstr\u00f6m M, Hugosson J, Lilja H, et al. Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps. BMJ Oncol. 2023;2(e000039):1\u201313.","DOI":"10.1136\/bmjonc-2023-000039"},{"key":"111872","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmjonc-2023-000039","DOI":"10.1136\/bmjonc-2023-000039"},{"key":"111873","doi-asserted-by":"crossref","unstructured":"Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Goteborg randomized population-based prostate cancer screening trial. Eur Urol. 2015;68:354\u201360.","DOI":"10.1016\/j.eururo.2014.12.006"},{"key":"111874","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2014.12.006","DOI":"10.1016\/j.eururo.2014.12.006"},{"key":"111875","doi-asserted-by":"crossref","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk factors \u2013 a systematic review. Eur Urol. 2023;84:191\u2013206.","DOI":"10.1016\/j.eururo.2023.04.021"},{"key":"111876","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021","DOI":"10.1016\/j.eururo.2023.04.021"},{"key":"111877","doi-asserted-by":"crossref","unstructured":"Goddard KAB, Feuer EJ, Umar A, Castle PE. Accelerating progress to reduce the cancer burden through prevention and control in the United States. J Natl Cancer Inst. 2025;117:20\u20138.","DOI":"10.1093\/jnci\/djae204"},{"key":"111878","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/jnci\/djae204","DOI":"10.1093\/jnci\/djae204"},{"key":"111879","doi-asserted-by":"crossref","unstructured":"Stranne J. 2023\/2024 update of the national prostate cancer guidelines in Sweden. Scand J Urol. 2024;59:210\u20131. https.\/\/doi.org\/10.2340\/sju.v59.42656","DOI":"10.2340\/sju.v59.42656"},{"key":"111880","doi-asserted-by":"crossref","unstructured":"Stattin P. How to improve cancer care by use of guidelines and quality registers. Scand J Urol. 2024;59:190\u20132.","DOI":"10.2340\/sju.v59.42272"},{"key":"111881","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/sju.v59.42272","DOI":"10.2340\/sju.v59.42272"},{"key":"111882","doi-asserted-by":"crossref","unstructured":"Tomic K, Berglund A, Robinson D, Hj\u00e4lm-Eriksson M, Carlsson S, Lambe M, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2015;54:158\u201363.","DOI":"10.3109\/0284186X.2014.939299"},{"key":"111883","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/0284186X.2014.939299","DOI":"10.3109\/0284186X.2014.939299"},{"key":"111884","doi-asserted-by":"crossref","unstructured":"Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort profile update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base \u2013 a refined prostate cancer trajectory. Int J Epidemiol. 2016;45:73\u201382.","DOI":"10.1093\/ije\/dyv305"},{"key":"111885","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/ije\/dyv305","DOI":"10.1093\/ije\/dyv305"},{"key":"111886","unstructured":"Statistics Sweden. Att m\u00e4ta segregation p\u00e5 l\u00e5g regional niv\u00e5. Reference no. 2017\/1421 [Report in Swedish]. [cited 2028 Mar 18]. Available from: https:\/\/www.scb.se\/contentassets\/deedfb3fbe3d4abd987cfcd67dcff2e4\/slutrapport-att-mata-segregation-pa-lag-regional-niva._ku2017_02404_d.pdf"},{"key":"111887","doi-asserted-by":"crossref","unstructured":"Str\u00f6mberg U, Baigi A, Holm\u00e9n A, Parkes BL, Bonander C, Piel FB. A comparison of small-area deprivation indicators for public-health surveillance in Sweden. Scand J Public Health. 2023;51:520\u20136.","DOI":"10.1177\/14034948211030353"},{"key":"111888","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/14034948211030353","DOI":"10.1177\/14034948211030353"},{"key":"111889","doi-asserted-by":"crossref","unstructured":"Allik M, Leyland A, Travassos Ichihara MY, Dundas R. Creating small-area deprivation indices: a guide for stages and options. Epidemiol Community Health. 2020;74:20\u20135.","DOI":"10.1136\/jech-2019-213255"},{"key":"111890","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/jech-2019-213255","DOI":"10.1136\/jech-2019-213255"},{"key":"111891","unstructured":"Breslow NE, Day NE. Statistical methods in cancer research, volume II: the design and analysis of cohort studies. Lyon: International Agency for Research on Cancer, World Health Organisation; 1987."},{"key":"111892","doi-asserted-by":"crossref","unstructured":"Blangiardo M, Cameletti M. Spatial and Spatio-temporal Bayesian models with R-INLA. New York, NY: Wiley; 2015.","DOI":"10.1002\/9781118950203"},{"key":"111893","doi-asserted-by":"crossref","unstructured":"Berglund A, Garmo H, Robinson D, Tishelman C, Holmberg L, Bratt O, et al. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. Eur J Cancer. 2012;48:75\u201384.","DOI":"10.1016\/j.ejca.2011.07.009"},{"key":"111894","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2011.07.009","DOI":"10.1016\/j.ejca.2011.07.009"},{"key":"111895","doi-asserted-by":"crossref","unstructured":"Li X, Sundquist K, Sundquist J. Neighborhood deprivation and prostate cancer mortality: a multilevel analysis from Sweden. Prostate Cancer Prostatic Dis. 2012;15:128\u201334.","DOI":"10.1038\/pcan.2011.46"},{"key":"111896","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/pcan.2011.46","DOI":"10.1038\/pcan.2011.46"},{"key":"111897","doi-asserted-by":"crossref","unstructured":"Tomic K, Ventimiglia E, Robinson D, H\u00e4ggstr\u00f6m C, Lambe M, Stattin P. Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study. Int J Cancer. 2018;142:2478\u201384.","DOI":"10.1002\/ijc.31272"},{"key":"111898","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ijc.31272","DOI":"10.1002\/ijc.31272"},{"key":"111899","doi-asserted-by":"crossref","unstructured":"J\u00e4rbur E, Holmberg E, Bj\u00f6rk-Eriksson T, Bratt O, Arnsrud Godtman R. Associations between socioeconomic factors and PSA testing in a population-based organised testing programme and routine healthcare: a register-based study of 50-year-old men. BMJ Oncol. 2024;3:1\u20137.","DOI":"10.1136\/bmjonc-2024-000400"},{"key":"111900","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmjonc-2024-000400","DOI":"10.1136\/bmjonc-2024-000400"},{"key":"111901","doi-asserted-by":"crossref","unstructured":"Hugosson J, Godtman RA, Carlsson SV, Aus G, Grenabo Bergdahl A, Lodding P, et al. Eighteen-year follow-up of the Goteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol. 2018;52:27\u201337.","DOI":"10.1080\/21681805.2017.1411392"},{"key":"111902","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2017.1411392","DOI":"10.1080\/21681805.2017.1411392"},{"key":"111903","doi-asserted-by":"crossref","unstructured":"Str\u00f6mberg U, Berglund A, Carlsson S, Thellenberg Karlsson C, Lambe M, et al. Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden. Int J Cancer. 2024;155:637\u201345.","DOI":"10.1002\/ijc.34932"},{"key":"111904","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ijc.34932","DOI":"10.1002\/ijc.34932"},{"key":"111905","doi-asserted-by":"crossref","unstructured":"Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, et al. Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study. Cancer Causes Control. 2013;24:383\u201390.","DOI":"10.1007\/s10552-012-0124-6"},{"key":"111906","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10552-012-0124-6","DOI":"10.1007\/s10552-012-0124-6"},{"key":"111907","doi-asserted-by":"crossref","unstructured":"Diez-Roux AV, Mair C. Neighborhoods and health. Ann N Y Acad Sci. 2010;1186:125\u201345.","DOI":"10.1111\/j.1749-6632.2009.05333.x"},{"key":"111908","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1749-6632.2009.05333.x","DOI":"10.1111\/j.1749-6632.2009.05333.x"},{"key":"111909","doi-asserted-by":"crossref","unstructured":"Str\u00f6mberg U. How can precision prevention be approached from a general population perspective within the field of cancer epidemiology? Acta Oncol. 2021;60:1272\u20134.","DOI":"10.1080\/0284186X.2021.1962544"},{"key":"111910","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2021.1962544","DOI":"10.1080\/0284186X.2021.1962544"},{"key":"111911","doi-asserted-by":"crossref","unstructured":"Seikkula H, Kaipia A, Bostr\u00f6m PJ, Malila N, Pitk\u00e4niemi J, Sepp\u00e4 K. Periodic trends in geographical variation of prostate cancer incidence and mortality in Finland between 1985 and 2019. Acta Oncol. 2022;61:1209\u201315.","DOI":"10.1080\/0284186X.2022.2112971"},{"key":"111912","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2022.2112971","DOI":"10.1080\/0284186X.2022.2112971"},{"key":"111913","doi-asserted-by":"crossref","unstructured":"Nugin H, Folkvaljon Y, Damber JE, Adolfsson J, Robinson D, Stattin P. Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden. Scand J Urol. 2018;52:277\u201384.","DOI":"10.1080\/21681805.2018.1512650"},{"key":"111914","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2018.1512650","DOI":"10.1080\/21681805.2018.1512650"},{"key":"111915","doi-asserted-by":"crossref","unstructured":"Str\u00f6mberg U, Parkes BL, Holm\u00e9n A, Peterson S, Holmberg E, Baigi A, et al. Disease mapping of early- and late-stage cancer to monitor inequalities in early detection: a study of cutaneous malignant melanoma. Eur J Epidemiol. 2020;35:537\u201347.","DOI":"10.1007\/s10654-020-00637-0"},{"key":"111916","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10654-020-00637-0","DOI":"10.1007\/s10654-020-00637-0"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/43399\/50134","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/43399\/50134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:04:28Z","timestamp":1756404268000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/43399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":62,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2025.43399","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}